MDxHealth Receives Nasdaq Minimum Bid Price Deficiency Notification

MDxHealth SA (MDXH), a precision diagnostics company focused on urology, announced on July 2, 2026, that it received a notification letter dated June 30, 2026, from The Nasdaq Stock Market LLC. The letter indicated that the company is not in compliance with Nasdaq Listing Rule 5550(a)(2), which requires a minimum bid price for continued listing on The Nasdaq Capital Market. This deficiency arose because the company’s ordinary shares had closed below $1.00 per share for 30 consecutive business days.

Nasdaq Listing Rule 5550(a)(2) mandates that listed securities maintain a minimum bid price of US$1.00 per share. According to Nasdaq Listing Rule 5810(c)(3)(A), a failure to meet this requirement occurs if the deficiency persists for 30 consecutive business days. MDxHealth has been granted a compliance period of 180 calendar days, until December 28, 2026, to regain compliance. To satisfy this requirement, the company’s ordinary shares must achieve a closing bid price of at least US$1.00 for a minimum of 10 consecutive business days.

This notification does not immediately impact the company's listing on The Nasdaq Capital Market. However, failure to regain compliance by the deadline could lead to potential delisting. MDxHealth's management has stated that its core business operations are not affected by the notification, and it intends to monitor the closing bid price of its ordinary shares. The company may consider various options, including a reverse share split of its outstanding ordinary shares, to regain compliance with the minimum bid price requirement.

Minimum bid price requirements are a standard practice across major stock exchanges, like Nasdaq, to ensure that listed companies maintain a certain level of market value and liquidity. These rules aim to protect investor confidence and uphold the overall integrity of the exchange. A company's inability to meet these requirements can adversely affect its ability to raise capital from public markets and create uncertainty among investors.

Market analysts are closely watching MDxHealth's response to this situation. While some analysts point to weak financial resilience, including negative equity, higher debt, and continued negative operating/free cash flow, they also acknowledge the company's guidance for strong core revenue growth as a potential offsetting factor. If MDxHealth does not regain compliance by the deadline, it may be eligible for an additional 180-day grace period, provided it meets other Nasdaq listing standards, though this is not guaranteed, and the ultimate risk of delisting remains.

The future performance of MDxHealth and its efforts to regain Nasdaq compliance will be a key focus for investors in the coming period. The market awaits to see if the company will implement measures such as a reverse stock split and the subsequent impact on its share price. The company's market position in urology-focused diagnostic solutions and its potential for revenue growth remain critical to its long-term outlook.